Genmab will receive a milestone payment of $50 million in its DARZALEX collaboration with Janssen Biotech, Inc.   In August 2012, Genmab granted Janssen the exclusive worldwide license to develop, manufacture and commercialize DARZALEX. Just over 5 years later, Janssen has confirmed that DARZALEX’s sales reached $1 billion in a calendar year, prompting the milestone payment.   “We continue to be pleased with the rapid uptake seen with DARZALEX since its initial launch and a...